Blue Crest Capital Management LTD Adverum Biotechnologies, Inc. Transaction History

Blue Crest Capital Management LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$2.87 - $5.92 $54,618 - $112,663	-19,031 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$4.5 - $7.6 $85,639 - $144,635	19,031 New	19,031 $115,000
Q2 2018 Aug 14, 2018	SELL	$5.3 - $6.9 $843,558 - $1.1 Million	-159,162 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$3.65 - $7.95 $465,269 - $1.01 Million	127,471 Added 402.23%	159,162 $923,000
Q4 2017 Feb 14, 2018	BUY	$2.85 - $3.95 $90,319 - $125,179	31,691	31,691 $111,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $471M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Blue Crest Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Blue Crest Capital Management LTD with notifications on news.